Progress is being made towards reaching a deal in the U.S.-Mexico-Canada trade agreement (USMCA) that will sharply reduce protections for biologic drugs, in what will be a setback for U.S. pharmaceutical companies, Mexico’s government said on Dec. 4.
The USMCA is a new North American trade pact approved by Mexico this year, but Democratic lawmakers have held up U.S. ratification urging the Trump administration to make several changes regarding steps on the drug protections.
